Novo Nordisk’s semaglutide set to tackle obesity with hotly-anticipated FDA green light

Novo Nordisk’s semaglutide set to tackle obesity with hotly-anticipated FDA green light
fkansteiner
Fri, 06/04/2021 – 14:12